178 related articles for article (PubMed ID: 20874640)
21. Therapeutic cancer vaccines.
Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
[TBL] [Abstract][Full Text] [Related]
22. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG
Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
24. Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules.
Bubeník J
Folia Biol (Praha); 1996; 42(6):295-304. PubMed ID: 9158939
[No Abstract] [Full Text] [Related]
25. Dendritic cells in cancer immunotherapy.
Schuler G
Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
[TBL] [Abstract][Full Text] [Related]
26. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
Sensi M; Anichini A
Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
[TBL] [Abstract][Full Text] [Related]
27. Optimizing T-cell expansion: have we reached the limit?
Melenhorst JJ
Cytotherapy; 2009; 11(7):813-4. PubMed ID: 19903094
[No Abstract] [Full Text] [Related]
28. Whole tumor cell vaccines for glioma immunotherapy.
Field CS; Hermans IF; Hunn MK
Immunotherapy; 2016; 8(4):387-9. PubMed ID: 26973119
[No Abstract] [Full Text] [Related]
29. Tumor reactive T cells get a boost.
Pardoll DM
Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
[No Abstract] [Full Text] [Related]
30. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
31. Tumor immunity and immunotherapy.
Boura P; Kountouras J; Lygidakis NJ
Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
[TBL] [Abstract][Full Text] [Related]
32. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
33. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
34. [Identification of human tumor antigens recognized by T cells].
Kawakami Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():562-7. PubMed ID: 15861711
[No Abstract] [Full Text] [Related]
35. Tumor immunology at the service of cancer immunotherapy.
Finn OJ
Curr Opin Immunol; 2004 Apr; 16(2):127-9. PubMed ID: 15023402
[No Abstract] [Full Text] [Related]
36. Vaccine therapy for cancer: fact or fiction?
Odunsi K; Lele S; Savalgi R
Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673
[TBL] [Abstract][Full Text] [Related]
37. Targeting the dendritic cell: the key to immunotherapy in cancer?
Faith A; Hawrylowicz CM
Clin Exp Immunol; 2005 Mar; 139(3):395-7. PubMed ID: 15730383
[No Abstract] [Full Text] [Related]
38. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
39. [A scientist's day-dream or future reality? Specific immunotherapy against cancer].
Kiessling R; Kärre K
Lakartidningen; 1997 Apr; 94(17):1595-600. PubMed ID: 9182159
[No Abstract] [Full Text] [Related]
40. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
